Author
Listed:
- O Fernández Calvo
- R C Ã lvarez Llosa
(Complejo Hospitalario Universitario Ourense, Ourense, Spain)
- T Alonso Gordoa
(Hospital Universitario Ramón y Cajal, Madrid, Spainia)
- N Láinez
(Complejo Hospitalario de Navarra, Pamplona, Spain)
- à RodrÃguez Sánchez
(Complejo Asistencial Universitario de León, León, Spain)
- G De Velasco
(Hospital Universitario 12 De Octubre, Madrid, Spain)
- U Anido
(Hospital ClÃnico Universitario de Santiago de Compostela, Santiago De Compostela, Spain)
- R GarcÃa Marrero
(Hospital Universitario Tenerife, Tenerife, Spain)
- E MartÃnez Ortega
(Hospital Universitario de Jaén, Jaén, Spain)
- A Viana
(Hospital Nuestra Señora del Prado, Talavera De La Reina, Spain)
- C Caballero Diaz
(Hospital General Universitario Valencia, Valencia, Spain)
- J GarcÃa Sánchez
(Hospital Arnau de Vilanova, Valencia, Spain)
- F Zambrana Tevar
(Hospital Infanta SofÃa, San Sebastián De Los Reyes, Spain)
- Ã Pinto MarÃn
(Hospital Universitario La Paz, Madrid, Spain)
- R Lastra
(Hospital San Jorge, Huesca, Spain)
- A RodrÃguez
(Hospital General de La Palma, Spain)
- C Perezagua
(Hospital de Henares, Coslada, Madrid, Spain)
- Ã Gaizka Montesa
(Hospital Carlos Haya, Málags, Spain)
- S Maciá
(ICON Clinical Research, Alicante, Spain)
- S Vázquez Estévez
(Hospital Universitario Lucus Augusti, Lugo, Spain)
Abstract
Cabazitaxel is approved as second line treatment for metastatic castration resistant prostate cancer (mCRPC) after docetaxel failure. However, it is difficult to establish which patients will reach benefit. In this study, we aimed to analyze retrospectively clinical characteristics for cabazitaxel long responding mCRPC patients.
Suggested Citation
O Fernández Calvo & R C à lvarez Llosa & T Alonso Gordoa & N Láinez & à RodrÃguez Sánchez & G De Velasco & U Anido & R GarcÃa Marrero & E MartÃnez Ortega & A Viana & C Caballero Diaz & J GarcÃa, 2020.
"Factors Influencing Long Term Survival in Metastatic Castration Resistant Prostate Cancer Patients a Spanish Multicentre Experience,"
Cancer Therapy & Oncology International Journal, Juniper Publishers Inc., vol. 16(1), pages 1-8, March.
Handle:
RePEc:adp:jctoij:v:16:y:2020:i:1:p:1-8
DOI: 10.19080/CTOIJ.2020.16.555926
Download full text from publisher
More about this item
Keywords
;
;
;
;
;
;
;
;
;
JEL classification:
- R00 - Urban, Rural, Regional, Real Estate, and Transportation Economics - - General - - - General
- Z0 - Other Special Topics - - General
Statistics
Access and download statistics
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:jctoij:v:16:y:2020:i:1:p:1-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.